Year: 2026
Type: article
Study design: Observational Study
Abstract: OBJECTIVE: Cenobamate (CNB) is a novel antiseizure medication with a dual mechanism of action that has demonstrated high efficacy in drug-resistant focal epilepsy; however, evidence in brain tumor-related epilepsy (BTRE) remains limited. The study aimed to evaluate the effectiveness, safety, and tolerability of CNB as add-on therapy in a multicenter cohort of patients with BTRE. METHODS: We conducted a multicenter, retrospective observational study across tertiary epilepsy centers in the Lazio region, Italy. Adult patients with drug-resistant BTRE treated with CNB as adjunctive therapy were included. Seizure frequency was assessed at baseline and during follow-up. Primary outcomes were changes in monthly seizure frequency and responder rates. Effectiveness was analyzed in both the overall population and in a homogeneous cohort of patients with 6-month follow-up. RESULTS: Twenty patients (10 females, median age 48 years) were included. Tumor histology included meningioma (n = 7, 35%), astrocytoma (n = 4, 20%), glioblastoma (n = 3, 15%), ganglioglioma (n = 3, 15%), oligodendroglioma (n = 2, 10%), and dysembryoplastic neuroepithelial tumor (n = 1, 5%). In the overall analysis population (n = 20), after a median 12-month follow-up, median seizure frequency significantly decreased from 6 to 1 per month (p < 0.001), with a median reduction of 85.8% (IQR 51.4-96.7). Responder rates were 80% (≥50% seizure reduction), 60% (≥75%), and 20% achieved seizure freedom. Adverse events occurred in 12 patients (60%), including sedation (n = 8, 40%), postural instability (n = 3, 15%), diarrhea, and mild cutaneous rash (n = 1, 5% each). CNB was discontinued in one patient (5%). SIGNIFICANCE: In this multicenter real-world cohort of patients with drug-resistant BTRE and heterogeneous tumor histology, CNB was associated with a reduction in seizure frequency and was well tolerated. PLAIN LANGUAGE SUMMARY: Seizures caused by brain tumors can be difficult to control. We reviewed records from 20 adults who received cenobamate alongside their existing seizure medicines. At their last follow-up, 16 had at least half as many seizures, and four were seizure-free. Twelve patients experienced side effects, most commonly sleepiness; one stopped cenobamate because of a rash. These findings suggest that cenobamate may help some people with brain tumor-related epilepsy. However, the study was small, had no comparison group, and included patients with different tumors and follow-up durations. Larger studies are needed.
Source: Epilepsia Open
DOI: 10.1002/epi4.70365
Authors: Marina Romozzi(Data curation, Formal analysis, Investigation, Visualization, Writing – original draft, Writing – review & editing), Adolfo Mazzeo(Data curation, Formal analysis, Investigation, Visualization, Writing – original draft, Writing – review & editing), Matteo Antonucci, Giovanni Assenza, Maria Antonietta Bassetti, Mariana Fernandes, Claudio Liguori, Giulia Lippa, Marta Piccioli, Patrizia Pulitano, Paolo Tisei, Mario Tombini, Paolo Calabresi, Catello Vollono, Marta Maschio(Methodology, Project administration, Supervision, Validation, Writing – review & editing)
Institutions: Università Cattolica del Sacro Cuore, Agostino Gemelli University Polyclinic, Istituti di Ricovero e Cura a Carattere Scientifico, Sapienza University of Rome, University of Rome Tor Vergata, Policlinico Tor Vergata, Università Campus Bio-Medico, Campus Bio Medico University Hospital, Azienda Ospedaliera San Giovanni Addolorata, ASL Roma, Ospedale San Filippo Neri
Language: English
Subfield: Clinical Neurology
Field: Medicine
Domain: Health Sciences
Keywords: cenobamate, brain tumor-related epilepsy, drug-resistant epilepsy, adjunctive antiepileptic therapy, seizure frequency reduction, seizure freedom, adverse events, sedation, tumor histology, meningioma, glioblastoma, astrocytoma, ganglioglioma, oligodendroglioma, dysembryoplastic neuroepithelial tumor, real-world effectiveness
Open Access status: gold
Estimated APC paid: $3,120
OpenAlex ID: W7234566140
